Eight weeks of mineralocorticoid blockade does not improve insulin sensitivity in type 2 diabetes

Individuals with type 2 diabetes have an increased risk of cardiovascular disease. A correlation between plasma aldosterone and hyperinsulinemia has been demonstrated in vivo, and hyperinsulinemia and insulin resistance are independently associated with the development of cardiovascular complication...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Physiological reports 2021-08, Vol.9 (15), p.e14971-n/a
Hauptverfasser:	Finsen, Stine H., Hansen, Mie R., Hoffmann‐Petersen, Joachim, Højgaard, Henrik F., Mortensen, Stefan P.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aldosterone Blood Glucose - analysis Cardiovascular disease Cardiovascular diseases Case-Control Studies Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - drug therapy Eplerenone - therapeutic use Female Glucose Humans Hyperinsulinemia Insulin Insulin - metabolism Insulin Resistance insulin sensitivity Kinases Male Middle Aged mineralocorticoid blockade Mineralocorticoid Receptor Antagonists - therapeutic use Musculoskeletal system Original Peptides Physiology Plasma Potassium Receptors, Mineralocorticoid - chemistry type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Individuals with type 2 diabetes have an increased risk of cardiovascular disease. A correlation between plasma aldosterone and hyperinsulinemia has been demonstrated in vivo, and hyperinsulinemia and insulin resistance are independently associated with the development of cardiovascular complications. We investigated if mineralocorticoid blockade (Eplerenone) improves insulin sensitivity in individuals with type 2 diabetes compared to healthy controls. We included 13 participants with type 2 diabetes (
ISSN:	2051-817X
DOI:	10.14814/phy2.14971